AgomAb Therapeutics NV (AGMB) Stock Forecast
AGMB analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.57 / 5 from 7 analysts
- Price target
- $37.67 average of analyst targets
- Upside to target
- +354.9% from the latest close
- Next earnings
- —
- 52-week range
- $8.28 – $17.82
AGMB analyst ratings
7 analystsNumber of analysts at each rating.
AGMB price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
AGMB earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.37 | −$0.41 | −$0.33 | — | — | 3 |
| Current fiscal year (2026) | −$1.83 | −$2.08 | −$1.58 | −$167.76 | +98.9% | 6 |
| Next fiscal year (2027) | −$2.05 | −$2.48 | −$1.46 | −$1.83 | −11.8% | 6 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
AGMB revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | — | 4 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 6 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 6 |
AGMB EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
AGMB EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.48 | −$0.48 | −$0.37 | −$0.37 | −$0.37 | −23.3% | 1 up · 0 down |
| Current fiscal year (2026) | −$1.81 | −$1.95 | −$1.85 | −$1.85 | −$1.83 | +1.0% | 0 up · 2 down |
| Next fiscal year (2027) | −$2.00 | −$2.13 | −$2.07 | −$2.07 | −$2.05 | +2.6% | 0 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
AGMB earnings surprises
Reported EPS vs the consensus estimate for the last 1 quarters; AGMB beat in 1 of 1.
What analysts expect from AGMB
7 analysts cover AgomAb Therapeutics NV; their consensus rating is strong buy (4.57 on a 1–5 scale, where 5 is a strong buy). The average price target is $37.67, 354.9% above the latest close of $8.28. Analysts expect earnings of −$1.83 per share for 2026, +98.9% from a year earlier. For 2027 the average estimate is −$2.05 per share. AgomAb Therapeutics NV beat the EPS estimate in 1 of the last 1 quarters.
Related: AGMB income statement, AGMB key metrics, AGMB chart. See the AGMB stock overview for the latest quote and news.
AGMB forecast FAQ
What is AgomAb Therapeutics NV's price target?
The average analyst price target for AgomAb Therapeutics NV is $37.67, 354.9% above the latest close of $8.28.
Is AgomAb Therapeutics NV a buy, hold or sell?
Of 7 analysts covering AgomAb Therapeutics NV, 4 rate it a strong buy, 3 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is AgomAb Therapeutics NV's EPS forecast?
Analysts forecast −$1.83 per share for 2026 (range −$2.08 to −$1.58); for 2027 the estimate is −$2.05.
Does AgomAb Therapeutics NV usually beat earnings estimates?
AgomAb Therapeutics NV reported EPS at or above the analyst estimate in 1 of the last 1 quarters.